When should I start lamotrigine extended‑release (ER) versus immediate‑release (IR) formulation?

When to Start Lamotrigine ER vs IR

Start with lamotrigine immediate-release (IR) for initial titration and dose optimization, then consider converting to extended-release (ER) if the patient experiences peak-related adverse effects (dizziness, blurred vision, diplopia, unsteadiness) or has persistent breakthrough seizures despite adequate IR dosing.

Initial Treatment Strategy

Begin all patients on lamotrigine IR for the following reasons:

• Dose titration flexibility: IR formulation allows for more precise dose adjustments during the critical titration phase, which is essential to minimize the risk of serious rash including Stevens-Johnson syndrome 1
• Established efficacy data: The evidence base for lamotrigine efficacy in epilepsy is primarily built on IR formulation studies 1
• Standard of care: IR remains the reference formulation for establishing therapeutic levels and clinical response

When to Convert from IR to ER

Consider switching to lamotrigine ER in these specific clinical scenarios:

Primary Indications for ER:

1. Peak-related adverse effects on IR formulation:

   • Dizziness, blurred vision, diplopia, or unsteadiness occurring 1-2 hours post-dose
   • These symptoms correlate with peak serum concentrations that occur rapidly with IR (Tmax 1-1.5 hours) 2

2. Incomplete seizure control despite adequate IR dosing:

   • 47% of patients converting from IR to ER experienced >50% reduction in seizure frequency
   • Median 46% overall reduction in seizures after conversion 3
   • Higher trough levels with ER may improve seizure threshold between doses 3

3. Adherence concerns:

   • Once-daily dosing simplifies regimen and improves compliance 4
   • ER formulation is more "forgiving" of missed doses, maintaining more stable concentrations 5

Pharmacokinetic Advantages of ER

The ER formulation provides:

• Reduced peak-to-trough fluctuation: Lower peak concentrations (reducing adverse effects) while maintaining higher trough levels (improving seizure control) 3, 2
• Extended Tmax: Peak occurs at 4-11 hours depending on concomitant medications, versus 1-1.5 hours for IR 2
• Maintained steady-state exposure: Trough concentrations remain similar between formulations at equivalent total daily doses 2

Conversion Protocol

When converting from IR to ER:

• Use the same total daily dose for most patients 2
• Exception: Patients on enzyme-inducing AEDs (phenytoin, carbamazepine) may need slight dose adjustment as ER AUC can be ~21% lower 2
• Monitor serum levels before and after conversion to ensure therapeutic range is maintained
• Conversion is straightforward and well-tolerated 2

Important Caveats

Do NOT start with ER in these situations:

• Initial lamotrigine therapy (need IR for careful titration)
• Patients requiring rapid dose adjustments
• When precise dose titration is needed for rash risk mitigation

Consider enzyme-inducing comedications: Patients taking phenytoin, carbamazepine, or other enzyme inducers metabolize lamotrigine faster, which affects both formulations but may require closer monitoring with ER 2

Adherence is not solely about formulation: While ER offers once-daily convenience, comprehensive adherence strategies should include therapeutic drug monitoring, patient education, and reminder systems 4

The evidence strongly supports starting with IR for safety and titration flexibility, then converting to ER as a therapeutic optimization strategy when specific clinical indications arise—particularly peak-related side effects or suboptimal seizure control 3.